Literature DB >> 1606524

IVIG in the treatment of children with acute and chronic idiopathic thrombocytopenic purpura and the autoimmune cytopenias.

D J Nugent1.   

Abstract

IVIG has been shown to be useful in the treatment of acute and chronic ITP, immune neutropenia, and in some cases of AIHA. The mechanism of action of IVIG is owing to a number of factors, which include Fc blockade, immune modulation of T- and B-cell number and function, alterations in NK activity, and direct effects on autoantibody binding and production via the antiidiotypic antibody network. Current research efforts are directed toward elucidation of these modalities and determination of their relative importance in treating patients with immune-mediated cytopenias.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1606524     DOI: 10.1007/978-1-4612-0417-6_5

Source DB:  PubMed          Journal:  Clin Rev Allergy        ISSN: 0731-8235


  49 in total

1.  Antinuclear antibodies in patients with chronic idiopathic autoimmune thrombocytopenia followed 2-30 years.

Authors:  S Panzer; E Penner; W Graninger; E Schulz; J S Smolen
Journal:  Am J Hematol       Date:  1989-10       Impact factor: 10.047

2.  Reversal of neutropenia with methotrexate treatment in patients with Felty's syndrome. Correlation of response with neutrophil-reactive IgG.

Authors:  J J Fiechtner; D R Miller; G Starkebaum
Journal:  Arthritis Rheum       Date:  1989-02

3.  Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies.

Authors:  N R Shulman; V J Marder; R S Weinrach
Journal:  Ann N Y Acad Sci       Date:  1965-06-30       Impact factor: 5.691

4.  The treatment of chronic idiopathic thrombocytopenia with anti-D (Rho) immunoglobulin: its effectiveness, safety and mechanism of action.

Authors:  B J Boughton; R Chakraverty; T P Baglin; A Simpson; G Galvin; P Rose; B Rohlova
Journal:  Clin Lab Haematol       Date:  1988

5.  Use of intravenous immunoglobulin in chronic lymphocytic leukemia.

Authors:  E C Besa
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

6.  A monoclonal anti-platelet antibody with decreased reactivity for autoimmune thrombocytopenic platelets.

Authors:  D Varon; S Karpatkin
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

7.  Autoimmune neutropenia in systemic lupus erythematosus.

Authors:  G Starkebaum; T H Price; M Y Lee; W P Arend
Journal:  Arthritis Rheum       Date:  1978-06

8.  Treatment of autoimmune hemolytic anemia with Vinca-loaded platelets.

Authors:  Y S Ahn; W J Harrington; J J Byrnes; L Pall; J McCrainie
Journal:  JAMA       Date:  1983 Apr 22-29       Impact factor: 56.272

9.  Rapid transient reversal of anemia and long-term effects of maintenance intravenous immunoglobulin for autoimmune hemolytic anemia in patients with lymphoproliferative disorders.

Authors:  E C Besa
Journal:  Am J Med       Date:  1988-04       Impact factor: 4.965

10.  Autoantibodies against platelet membrane glycoproteins in children with acute and chronic immune thrombocytopenic purpura.

Authors:  P Berchtold; R McMillan; P Tani; S Sommerville-Nielsen; V S Blanchette
Journal:  Blood       Date:  1989-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.